Astaxanthin / Risk Cancer Research Results

ASTX, Astaxanthin: Click to Expand ⟱

Features:

Astaxanthin — a lipophilic xanthophyll carotenoid antioxidant (often sourced from Haematococcus pluvialis microalgae and also present in salmon/crustaceans) used as a nutraceutical with prominent redox and inflammation-modulating biology. It is formally classified as a small-molecule dietary carotenoid (natural product / nutraceutical). Common abbreviations include ASTX and AXT. In oncology-context literature it is primarily discussed as a chemopreventive/cytoprotective redox modulator with context-dependent direct antitumor effects, and with theoretical concern for antagonizing ROS-mediated chemo/radiation mechanisms in some settings.
The European Commission considers natural astaxanthin as a food dye

Primary mechanisms (ranked):

NRF2 pathway activation with downstream antioxidant/phase-II enzyme program (context-dependent; often cytoprotective)
Suppression of inflammatory signaling including NF-κB axis with downstream COX-2/iNOS and cytokine modulation
Growth/survival signaling modulation (context-dependent), commonly reported on PI3K–AKT, ERK/MAPK, STAT3
Mitochondria-linked apoptosis induction and cell-cycle perturbation in select tumor models (dose/model-dependent)
Anti-migration/anti-EMT phenotype (e.g., MMPs, cadherin switch; model-dependent)
Ferroptosis/redox-lethal interactions reported in limited models (model-dependent)

Bioavailability / PK relevance: Poor aqueous solubility and variable oral absorption (fat/formulation-dependent). Plasma exposure is typically low with standard oral supplements; engineered formulations (micellar/nanoemulsion) can increase Cmax and shorten Tmax. Reported terminal half-life in healthy volunteers is on the order of ~1–2 days in at least one human PK study.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar astaxanthin concentrations that can exceed typical human plasma levels after supplementation; therefore, mechanistic claims are frequently concentration- and formulation-limited for systemic antitumor translation.

Clinical evidence status: Predominantly preclinical (cell/animal) for direct anticancer claims. Human evidence is stronger for oxidative stress/inflammation biomarker modulation than for anticancer efficacy endpoints; not an approved anticancer drug. Practical oncology use is mainly adjunctive/chemopreventive framing, with caution discussed around concurrent ROS-dependent chemo/radiation.

Astaxanthin is a xanthophyll carotenoid with exceptionally strong antioxidant capacity. In cancer biology, it shows context-dependent effects—largely chemopreventive and cytoprotective, with limited evidence as a direct antineoplastic agent.
Astaxanthin significantly promotes the proliferation of Akkermansia, a microorganism with enhanced anti-tumor immune effects.
Anti-inflammatory signaling, Astaxanthin can inhibit: NF-κB, COX-2, iNOS
Astaxanthin commonly Activates NRF2: Upregulates antioxidant enzymes (GSH, SOD, CAT, GPX)
-Protective in normal tissues
-Potentially tumor-protective in established cancers

Often discouraged during active chemotherapy or radiation
It may:
-Protect tumor cells from ROS-mediated killing
-Reduce lipid peroxidation-based therapies
This concern is similar to:
-Vitamin E
-Trolox
-High-dose carotenoids

Astaxanthin is less likely to be pro-oxidant than lycopene or β-carotene.
Some reports indicate a pro-oxidant effect, but at concentrations that are not achievable for in vito.

Astaxanthin — mechanistic pathway map (cancer-context)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	NRF2 antioxidant response	↑ NRF2 (context-dependent) → ↓ ROS injury; may blunt ROS-lethal therapies	↑ NRF2 → ↑ GSH/SOD/CAT/GPx; cytoprotection	R/G	Redox buffering and stress tolerance	Often positioned as protective; in established tumors this can be tumor-supportive depending on therapy and redox state.
2	NF-κB inflammatory signaling	↓ NF-κB → ↓ pro-survival inflammation (model-dependent)	↓ inflammatory cytokine signaling	R/G	Anti-inflammatory microenvironment shift	Commonly linked to ↓ COX-2/iNOS and reduced inflammatory tone.
3	PI3K–AKT survival signaling	↓ PI3K/AKT (model-dependent) → ↑ apoptosis, ↓ proliferation	↔ / mild cytoprotective bias (context-dependent)	R/G	Survival pathway suppression in select tumors	Directionality is model- and dose-dependent; some datasets show mixed AKT effects.
4	ERK/MAPK signaling	↓ ERK/MAPK (model-dependent) → ↓ proliferation/EMT	↔ / ↓ stress-activated signaling (context-dependent)	R/G	Anti-growth signaling modulation	Often reported alongside PI3K/AKT changes; may converge on apoptosis/cell-cycle effects.
5	STAT3 axis	↓ STAT3 → ↓ proliferation, ↓ immune-evasion programs (model-dependent)	↔	G	Reduced oncogenic transcription signaling	Reported in prostate and other models; typically framed as anti-tumor signaling.
6	Mitochondria-mediated apoptosis	↑ intrinsic apoptosis (BAX↑, Bcl-2↓, caspases↑; model-dependent)	↓ stress-induced apoptosis (cytoprotection)	R	Cell death modulation	Key “anti-tumor” readout in many studies; may require higher concentrations than typical systemic exposure.
7	Cell cycle control	↑ p21/p27 and/or arrest signatures (model-dependent)	↔	G	Proliferation braking	Often co-occurs with apoptosis; direction varies with cell line and dosing.
8	EMT and matrix remodeling	↓ EMT; ↓ MMPs; ↑ E-cadherin (model-dependent)	↔	G	Anti-migration / anti-metastatic phenotype	Reported via miRNA and cadherin/MMP changes in some colon/breast models.
9	Angiogenesis signaling	↓ VEGF/EGFR signaling (limited, model-dependent)	↔	G	Reduced pro-angiogenic drive	Less consistently central than NRF2/NF-κB/PI3K–AKT in the literature.
10	Ferroptosis and lipid peroxidation balance	↔ / ↑ ferroptosis (limited models) but also ↓ lipid peroxidation (context-dependent)	↓ lipid peroxidation injury	R	Redox-lethal interaction or protection (context-dependent)	Net effect depends strongly on baseline oxidative state and whether therapy relies on lipid peroxidation.
11	Clinical Translation Constraint	Low/variable oral exposure; many in-vitro effects are high-concentration. Antioxidant/NRF2 biology raises a plausible antagonism risk for ROS-dependent chemo/radiation (context-dependent). Formulation and dosing strategy strongly influence exposure.		—	Translational ceiling	Best-supported human domain is oxidative stress/inflammation biomarkers rather than anticancer efficacy endpoints.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr

Risk, Risk: Click to Expand ⟱

Source:

Type:

Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.

Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral


CRIS  Exposure / Compound  Evidence  Cancers  Notes


-5  Exercise (overall)
VStrong Hum  BC, CRC, Endo, PCa, Liv
↓insulin/IGF-1, ↓inflammation, ↑immune surveillance, ↓hormones



-5  Aerobic + resistance  VStrong Hum  Broad inc + mort
Best overall exercise synergy



-4  Aerobic exercise (mod–vig)  VStrong Hum  BC, CRC, Endo
Dose–response; ↓visceral fat



-4  Resistance training (alone)  Strong Hum  BC, CRC
↑insulin sensitivity; ↑lean mass



-3  High-intensity interval training  Mod–Strong Hum  BC, CRC
↑AMPK; ↑mitochondrial function; adherence matters



-2  NEAT / low-intensity activity  Moderate Hum  CRC
↓sedentary harm



-5  Cruciferous vegetable pattern  Strong Hum  Lung, CRC, BC, PCa
↑NRF2, ↓CYP1; ITC synergy



-5  Sunlight exposure (physiologic)  Strong Hum  CRC, BC, PCa
↑circadian alignment, ↑immune effects beyond vitamin D



-4  Fasting (metabolic pattern)
Strong Mech + Hum  BC, CRC, PCa 
↓IGF-1, ↓mTOR, ↑autophagy



-4  Curcumin
Hum + Pre  GI, BC, PCa
↓NF-κB, ↓STAT3



-4  Sulforaphane
Hum + Pre  Lung, CRC, BC
↑NRF2, ↓HDAC



-4  PEITC
Hum + Pre  Lung, CRC, PCa
↓CYP1A2, ↑apoptosis



-4  EGCG (tea matrix)
Strong Hum  GI, PCa, BC
↓angiogenesis; tea matrix superior to extract



-4  Lycopene
Strong Hum  PCa
↓oxidative DNA damage



-4  Apigenin
Pre + Diet Hum  BC, PCa, CRC 
↓PI3K-AKT, ↑p53



-4  Luteolin
Pre + Diet Hum  Lung, CRC, BC 
↓STAT3, ↓EMT



-4  Kaempferol
Diet Hum  Ov, Panc, Lung
↓VEGF, ↑apoptosis



-4  Fisetin
Pre + Early Hum  CRC, PCa, Mel
↓mTOR; senolytic activity



-4  Ellagic acid → Urolithin A
Hum (microbiome)  CRC, PCa, BC
↑mitophagy, ↓ER/AR signaling



-3  Omega-3 (EPA/DHA)
Strong Hum  CRC, BC
↓inflammation, ↓COX-2



-3  Vitamin D3 (supp)
Obs + RCT  CRC, BC
U-shaped response; ↓proliferation



-3  Garlic (allicin)
Mod Hum  GI
↓inflammation, ↓H. pylori



-3  Mushroom beta-glucans
Hum adjunct  GI, BC
↑NK cells, ↑immune surveillance



-3  Melatonin
Hum + Mech  BC, PCa
↓estrogen signaling, ↑circadian regulation



-3  Coffee (whole)
Strong Hum  Liv, Endo
↓fibrosis, ↓inflammation



-2  Quercetin
Limited Hum  Lung, CRC
Senolytic; ↓PI3K signaling



-2  Resveratrol
Limited Hum  CRC, BC
↓NF-κB; low bioavailability



-2  I3C / DIM
Mod Hum  BC, Cerv
↑2-OH estrogen, ↓ER signaling



-2  Thymoquinone
Early Hum  BC, CRC
↑apoptosis, ↓NF-κB



-2  Beta-carotene (food)
Hum  Lung
Antioxidant only in whole-food context



-1  Vitamin K2 (MK-4/7)
Limited Hum  Liv, PCa
↓proliferation, ↑differentiation



-1  Boron
Obs  PCa, Lung
↓inflammation; hormone modulation



0  Vitamin C (oral)
Strong Hum  —
Neutral overall effect



0  Genistein (soy)
Strong Hum  BC, PCa
Timing-dependent effects



0  Selenium (diet)
Mixed Hum  PCa
Narrow therapeutic window



0  Capsaicin
Mixed  Gastric
Dose-dependent effects



+2  Vitamin E (alpha only)
Strong RCT  PCa
Increased risk signal



+2  Green tea extract (high-dose)
Case reports  Liv
Hepatotoxicity reported



+4  Beta-carotene (supplement)
Strong RCT  Lung (smokers)
Increased lung cancer risk in smokers



+5  Alcohol (ethanol)
Strong Hum  BC, Liv, Eso
Linear increase in cancer risk




Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use

Scientific Papers found: Click to Expand⟱

5427-

ASTX,

Astaxanthin and Cancer Chemoprevention

Review,

Var,

chemoP↑, AntiCan↑, chemoPv↑, Risk↓, lipid-P↓, Pain↓, BioAv↑, Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Risk, Risk

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:382  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

Astaxanthin / Risk Cancer Research Results

Astaxanthin — mechanistic pathway map (cancer-context)

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Drug Metabolism & Resistance ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Home Page